Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Nearly half of patients with cancer are diagnosed at 70 years or older, which presents challenges in cancer care due to their high comorbidity burden and the underrepresentation of this age group in clinical trials. This retrospective study evaluated the association between comorbidity burden and immune checkpoint inhibitors (ICIs) treatment outcomes among older adults.
Methods: Data were collected from patients aged 70 years or older at the time of diagnosis who were treated with ICIs from 2011 to 2022. Key clinical outcomes include changes in performance status, overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs) and were compared between low baseline Charlson Comorbidity Index (CCI) and high CCI (<4 vs. ≥4) groups.
Results: Among 1,223 patients, patients with CCI scores ≥4 ( = 300) had a significantly shorter OS (11.4 vs. 13.6 months, = 0.0461) but similar PFS (8.0 vs. 7.7 months, = 0.258) compared to patients with CCI scores <4. There was no significant difference in changes in performance status pre- and post-treatment ( = 0.14) or in the irAE prevalence between the two groups (39.3% vs. 38.3%, = 0.786).
Conclusion: Our study suggests that ICIs are safe in patients with high comorbidity burden but that the presence of pre-treatment comorbidities decreases overall survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150610 | PMC |
| http://dx.doi.org/10.1080/14796694.2025.2502313 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-line treatment options for metastatic urothelial carcinoma: balancing efficacy, safety, and individual values and preferences through shared decision making.
Int J Clin Oncol
September 2025
Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, 305-8575, Japan.
Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.
View Article and Find Full Text PDFBibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000-2025).
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, China.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are increasingly linked to immune-related kidney injury (irKI). This study presents the first bibliometric analysis of irKI research (2000-2025), aiming to identify key trends, mechanistic insights, and pharmacological risk factors. We analyzed 2,179 publications to understand the evolution of irKI research, focusing on areas like T cell-mediated tubular injury, immune system-driven inflammation, and changes in metabolism.
View Article and Find Full Text PDFChoosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?
Medicine (Baltimore)
September 2025
Department of Radiotherapy, Shaoxing Second Hospital, Shaoxing, Zhejiang, China.
Background: This study addresses the lack of a comprehensive meta-analysis comparing the efficacy and safety of first-line anti-blocking the programmed cell death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) therapies in patients with extensive-stage small-cell lung cancer, using reconstructed individual patient data.
Methods: Through systematic review, we extracted relevant studies from PubMed and EMBASE databases, spanning January 1, 2010 to November 28, 2024. Only phase III randomized controlled trials assessing anti-PD-1 inhibitors plus chemotherapy (CT) versus anti-PD-L1 inhibitors plus CT were selected.
Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis.
J Infect Dev Ctries
August 2025
Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
Introduction: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized.
View Article and Find Full Text PDFHematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.
Asia Pac J Clin Oncol
September 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Background: In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development of immune-related adverse events (irAEs) remains unclear.
Methods: We conducted a multicenter retrospective cohort study to evaluate whether pre-treatment hematological markers-including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and the CRP-albumin-lymphocyte (CALLY) index-predict the development of irAEs in 147 patients with R/M SCCHN treated with pembrolizumab.